```text
Wiki Article
Abciximab (C7E3, 143653-53-6): A Research Reagent Overview
Abciximab, also identified as C7E3 or bearing the CAS number 143653-53-6, is a a valuable research reagent extensively utilized in platelet investigations. This monoclonal antibody fragment specifically targets the glycoprotein IIb/IIIa complex on thrombocytes , blocking thrombus development. Therefore , it's often applied as a method to analyze the processes underlying clotting and to evaluate the effectiveness of anticoagulant therapies. Availability is typically limited to research settings.
```
The Abciximab Compound Research: Utilizing C7E3 and Compound 143653-53-6 in Studies
Ongoing research into abciximab, a antiplatelet agent, frequently incorporates the monoclonal protein C7E3 and the chemical compound identified as 143653-53-6. These materials are essential for investigating abciximab's mode of function, evaluating its therapeutic effect in experimental conditions, and exploring potential indicators of patient outcome. Continued study leveraging these specific reagents is likely to yield valuable data for improving clinical applications related to cardiovascular illness.
```text
C7E3 abciximab, also known as c7e3fragment, is a GPIIb/IIIa receptor antagonist widely utilized in scientific research. Its primary application lies in platelet aggregation studies, allowing investigators to probe the mechanisms underlying thrombosis and hemostasis. Researchers employ this agent to investigate the role of platelet activation in various disease models, including ischemia-reperfusion injury and inflammation. Beyond basic research, abciximab is increasingly used in developing novel antithrombotic therapies and evaluating their efficacy. Furthermore, studies exploring its potential to modulate vascular smooth muscle cell function and reduce intracranial bleeding are ongoing. The availability of c7e3 abciximab facilitates a deeper understanding of platelet-mediated processes and contributes to the advancement of translational medicine. }
```
```text
Investigating Research Avenues with Abciximab 143653-53-6 using C7E3
Recent research demonstrate that this antiplatelet agent (identified as 143653-53-6) offers significant scientific promise, particularly when paired with C7E3. Preliminary findings indicated that this pairing might improve patient results in several cardiovascular settings. Further exploration is directed on defining the exact mechanism of action between the antiplatelet medication and C7E3, involving study of thrombocyte cohesion and vascular preservation.
- Current research endeavors intend to maximize administration protocols.
- Preclinical models are are being utilized to additional confirm these theories.
- Patient assessments might be necessary to thoroughly determine therapeutic benefit.
```
Abciximab (C7E3) for Research: Quality and Characteristics (143653-53-6)
Researchers needing C7E3 for laboratory studies should rigorously evaluate purity and precise parameters . This product is typically provided as a lyophilized powder and comprehensive analytical documentation including verification by LC-MS, biological activity assays, and bacterial endotoxin testing are available. Ensure the source’s certificate of analysis specifies defined values for related substances and meets established quality control standards here .
High-Purity Abciximab Details & Supply
Acquiring analytical-grade Abciximab, specifically referencing the molecule C7E3 and identified by the catalog number 143653-53-6, requires thorough consideration of its manufacturer. This agent is frequently utilized in laboratory studies , particularly those related to platelet adhesion and clotting . Current vendors offer this reagent in varying amounts , typically ranging from g to larger commercial quantities . Kindly suggest reviewing the documentation of testing to verify quality and applicability for your specific application . Moreover, check the expiration date before obtaining to maintain maximum performance .
- Standard Purity: >95%
- Keeping Conditions: -20°C in controlled conditions
- Application : Platelet Adhesion Suppression Studies